Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05VXF
|
||||
| Former ID |
DIB013596
|
||||
| Drug Name |
YSCMA
|
||||
| Synonyms |
YS-110; Anti-CD26 humanized antibody (cancer), Y's Therapeutics/Kissei Pharmaceutical
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Hematological malignancies [ICD9: 200-209; ICD10:C81-C86] | Phase 1/2 | [1] | ||
| Company |
Y's Therapeutics Co Ltd
|
||||
| Target and Pathway | |||||
| Target(s) | Dipeptidyl peptidase IV | Target Info | [2] | ||
| KEGG Pathway | Protein digestion and absorption | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031210) | ||||
| REF 2 | Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue. Diagn Pathol. 2014 Feb 6;9:30. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.